September 14, 2026: Understanding a New Treatment Option for HER2-Positive Gastric Cancer
This educational webinar provided an overview of HER2-positive gastric cancer, the role of biomarker testing in identifying eligible patients for targeted therapy, and emerging treatment advances that may help improve outcomes for those living with this disease.
During the webinar, participants heard from Samuel J. Klempner, MD, FASCO, who discussed:
– The importance of HER2 biomarker testing in gastric cancer
– Current treatment approaches for HER2-positive disease
– New treatment options and clinical data
– Practical considerations for patients, caregivers, and healthcare teams
This webinar supported awareness and education within the gastric cancer community and provided advocacy organizations, patient navigators, and other stakeholders with information they could share with the patients and families they serve.
